What is Retatrutide 10MG & 15MG

Retatrutide 10MG & 15MG is a synthetic tri-receptor agonist targeting GLP-1, GIP, and Glucagon receptors, studied in research for producing unparalleled levels of weight loss and metabolic correction. It is intended exclusively for research use.

Regarding its chemical identity, Retatrutide has a molecular formula of C221H342N46O68 and a molecular weight of ~4700 g/mol. Its reported canonical sequence is Synthetic Tri-Agonist Analogue. A confirmed CAS number is not available in open primary reference sources and is therefore omitted.

Its synonyms include Retatrutide.

Product for research use.

Mechanism of action of Retatrutide

Retatrutide uniquely activates three major metabolic pathways simultaneously. GLP-1 agonism suppresses appetite and regulates insulin. GIP agonism enhances insulin sensitivity and reduces nausea. Glucagon agonism directly increases energy expenditure, thermogenesis, and the rapid clearing of fat from the liver.

Pharmacokinetics and pharmacodynamics of Retatrutide

Engineered with a complex fatty diacid side chain to significantly extend its half-life, allowing for once-weekly dosing. The molecule is carefully balanced to ensure the three receptor activations act synergistically without causing severe hyperglycemia or tachycardia.

Scientific evidence on Retatrutide

The available evidence on Retatrutide is preliminary and largely inconclusive, and should be interpreted with caution. The literature describes it as having been investigated for multiple indications in preclinical models.

Currently one of the most heavily researched metabolic compounds globally (developed by Eli Lilly). Phase 2 clinical trial data showed unprecedented weight loss (up to 24% of body weight in 48 weeks) and complete resolution of non-alcoholic fatty liver disease (NAFLD) in many models.

Retatrutide applications in research

Ideal for (research context):
– In vitro and preclinical studies of its specific receptor pathways.
– Investigation of tissue repair, cell proliferation, and functional restoration in laboratory models.
– Comparative work with related peptides.

Not applicable for:
– clinical, diagnostic or therapeutic use.
– Any administration to humans or animals outside of an authorized research protocol.

Product for research use.

Retatrutide protocols in preclinical studies

The literature consulted does not include numerical doses from studies that can be cited for Retatrutide, so no trial schemes or quantities are specified.

The presentations of this product (10MG & 15MG) refer only to the amount of lyophilized peptide per vial (or volume for liquids) and do not constitute a dosage recommendation. The design of any protocol, including concentrations and working volumes, is the responsibility of the researcher, based on their experimental objectives and the relevant primary literature.

Information provided exclusively for research purposes.

Reconstitution and manipulation of Retatrutide

As a general guideline for laboratory handling, lyophilized peptides such as Retatrutide are usually reconstituted with bacteriostatic water (sterile water with approximately 0.9% benzyl alcohol).

Add the solvent slowly down the side of the vial, letting it run over the lyophilized powder; avoid injecting the stream directly onto the powder.
Do not shake: gently rotate the vial until completely dissolved.
Adjust the solvent volume according to the desired working concentration, considering the 10MG & 15MG contents of the vial.

These guidelines are for general technique and do not replace the internal procedures of each laboratory.

Retatrutide Stability and Storage

As a standard laboratory handling procedure for peptides:

Freeze-dried (unreconstituted): This is the most stable form. It is best preserved by freezing and protecting it from moisture and light for long-term storage.
Reconstituted: once in solution, the peptide is less stable and must be kept refrigerated, being used within a short period; for extended storage, freezing in aliquots is usually preferred.
Avoid repeated freeze-thaw cycles, as they can degrade the peptide.

Given that the molecule is characterized by rapid enzymatic degradation in biological media, careful cold chain management is especially relevant.

Documented Retatrutide security profile

The documented safety information in open sources for Retatrutide is limited and should be interpreted with caution, also considering that it is research material and not for clinical use.

Given its extreme potency and tri-receptor activation, it carries theoretical and observed risks of significant gastrointestinal distress, increased resting heart rate, and cardiac arrhythmias if mismanaged. Unverified for long-term safety outside of structured clinical trials.

Formal contraindications and adverse event rates are not available in the consulted literature, so no figures are reported.

Retatrutide in a comparative context

Retatrutide is the “triple G” successor to Tirzepatide (which targets GLP-1 and GIP). By adding the Glucagon receptor into the mix, Retatrutide attacks obesity from three distinct angles, making it theoretically the most potent anti-obesity peptide ever developed.

History and development of Retatrutide

Represents the current pinnacle of incretin mimetic research. Following the success of single (Semaglutide) and dual (Tirzepatide) agonists, researchers successfully stabilized a triple agonist, pushing the boundaries of pharmacological weight loss.